EMA explains how firms can avoid common problems in drug trial master files
This article was originally published in SRA
Executive Summary
The European Medicines Agency is inviting feedback on a draft reflection paper that explains how companies can comply with good clinical practice (GCP) requirements in relation to trial master files, whether these are maintained in paper or electronic formats1.